Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Average Rating of “Moderate Buy” by Analysts

Zealand Pharma A/S (OTCMKTS:ZLDPF) has been given an average rating of “Moderate Buy” by the eight analysts that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and three have given a strong buy rating to the company.

Several equities analysts have commented on ZLDPF shares. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. BTIG Research upgraded Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. BNP Paribas Exane downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th.

Zealand Pharma A/S Stock Performance

OTCMKTS ZLDPF opened at $39.79 on Friday. The company has a market cap of $2.83 billion, a P/E ratio of 2.91 and a beta of 0.75. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.10 and a quick ratio of 14.10. The stock has a 50-day moving average of $62.79 and a two-hundred day moving average of $70.46. Zealand Pharma A/S has a 1-year low of $35.93 and a 1-year high of $101.29.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.53. The company had revenue of $10.79 million for the quarter, compared to analyst estimates of $19.69 million. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 49.76%. As a group, analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.